Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Mirtazapine and Benzodiazepine in Acute Anxiety
KCT0007558Phase 4
Key facts
- Status
- Not yet recruiting
- Start
- Jul 2022
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- mirtazapine
- Conditions
- anxiety disordermajor depressive disorder (MDD)
01
Overview
Phase 4, randomised trial of mirtazapine in anxiety disorder and major depressive disorder (MDD) (2 arms), sponsored by Hyundai Pharmaceutical Co., Ltd. Planned start Jul 2022; status: not yet recruiting.
02
Design
2 arms- Study design
- Randomized
Mirtazapine arm
Participants receive mirtazapine for acute anxiety in the context of major depressive disorder.
Benzodiazepine arm
Participants receive a benzodiazepine for acute anxiety in the context of major depressive disorder.
03
Who it enrols
Adults with major depressive disorder experiencing acute anxiety symptoms; detailed inclusion and exclusion criteria were not provided in the registry entry.
Beyond the preview
Go deeper on KCT0007558.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007558.